Cargando…

Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia

Patients within the WHO-subgroup of t(6;9)-positive acute myeloid leukemia (AML) differ from other AML subgroups as they are characterised by younger age and a grim prognosis. Leukemic transformation can often be attributed to single chromosomal aberrations encoding oncogenes, in the case of t(6;9)-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiriches, Claudia, Khan, Dilawar, Wieske, Maria, Guillen, Nathalie, Rokicki, Michal, Guy, Carol, Wilson, Marieangela, Heesom, Kate J., Ottmann, Oliver Gerhard, Ruthardt, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463248/ https://www.ncbi.nlm.nih.gov/pubmed/35941390 http://dx.doi.org/10.1007/s00277-022-04905-9

Ejemplares similares

Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation
por: Chiriches, Claudia, et al.
Publicado: (2022)

P546: MACHINE LEARNING AND RESPONSE TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Elhaddad, Heba, et al.
Publicado: (2023)

LEF-1 drives aberrant β-catenin nuclear localization in myeloid leukemia cells
por: Morgan, Rhys G., et al.
Publicado: (2019)

STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML
por: Oancea, Claudia, et al.
Publicado: (2014)

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukemia
por: Rafiei, Anahita, et al.
Publicado: (2015)

Secretory factors from OP9 stromal cells delay differentiation and increase the expansion potential of adult erythroid cells in vitro
por: Trakarnsanga, Kongtana, et al.
Publicado: (2018)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study
por: Kayser, Sabine, et al.
Publicado: (2020)

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)
por: Ong, F., et al.
Publicado: (2022)

Quantitative phospho-proteomics reveals the Plasmodium merozoite triggers pre-invasion host kinase modification of the red cell cytoskeleton
por: Zuccala, Elizabeth S., et al.
Publicado: (2016)

Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
por: Badura, Susanne, et al.
Publicado: (2013)

The Challenge of t (6;9) and FLT3-Positive Acute Myelogenous Leukemia in a Young Adult
por: Song, Yeohan, et al.
Publicado: (2014)

PB1837: ANTIBIOTICS; A POSSIBLE ALTERNATE TREATMENT OPTION FOR MYELOID LEUKEMIA
por: Maham, Syeda, et al.
Publicado: (2023)

P456: LEUKEMOGENESIS BY AML-SPECIFIC DRIVER MUTATIONS WITHIN DNMT3A, IDH2 AND NPM1
por: Mehmetbeyoglu, Ecmel, et al.
Publicado: (2023)

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines
por: Gwanmesia, Patricia Mambou, et al.
Publicado: (2009)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Subcellular localization of full-length human myeloid leukemia factor 1 (MLF1) is independent of 14-3-3 proteins
por: Molzan, Manuela, et al.
Publicado: (2012)

P1460: INDUCTION OF FETAL HEMOGLOBIN BY TARGETED DELETION OF ZINC FINGER DOMAIN WITHIN BCL11A GENE USING CRISPR-CAS9 TECHNOLOGY
por: Hussain, Irfan, et al.
Publicado: (2023)

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)

MTAP-related increased erythroblast proliferation as a mechanism of polycythaemia vera
por: Tipgomut, Chartsiam, et al.
Publicado: (2021)

CDK9 inhibitors in acute myeloid leukemia
por: Boffo, Silvia, et al.
Publicado: (2018)

Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options
por: Lang, Fabian, et al.
Publicado: (2017)

The DAC system and associations with acute leukemias and myelodysplastic syndromes
por: Bug, Gesine, et al.
Publicado: (2010)

Lipidomic approach for stratification of acute myeloid leukemia patients
por: Stefanko, Adam, et al.
Publicado: (2017)

Crosstalk between b-catenin and WT1 signaling activity in acute myeloid leukemia
por: Wagstaff, Megan, et al.
Publicado: (2022)

Chronic myeloid leukemia
por: Hantschel, Oliver
Publicado: (2019)

Qualitative and Quantitative Comparison of the Proteome of Erythroid Cells Differentiated from Human iPSCs and Adult Erythroid Cells by Multiplex TMT Labelling and NanoLC-MS/MS
por: Trakarnsanga, Kongtana, et al.
Publicado: (2014)

The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis
por: Mian, Afsar A., et al.
Publicado: (2019)

Synthesis of 6-Methoxy-1-oxaspiro[4,5]deca-6,9-diene-8-one
por: Plourde, Guy L., et al.
Publicado: (2002)

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
por: Kuendgen, Andrea, et al.
Publicado: (2011)

Dionysus in 69 /
Publicado: (1970)

Unified classification and risk-stratification in Acute Myeloid Leukemia
por: Tazi, Yanis, et al.
Publicado: (2022)

Hemophagocytosis by acute myeloid leukemia blasts associated to poor clinical outcomes
por: Ouedraogo, Zangbéwendé Guy, et al.
Publicado: (2022)

RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations
por: Brabetz, Oliver, et al.
Publicado: (2017)

SPSC Meeting 69
por: Mannelli, M, et al.
Publicado: (2004)

Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
por: Hohmann, Anja F., et al.
Publicado: (2016)

Prognostic impact of MYH9 expression on patients with acute myeloid leukemia
por: Yu, Mengxia, et al.
Publicado: (2016)

Erratum: Vol. 69, No. 5
por: Ahmed, Faruque, et al.
Publicado: (2020)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
por: Ottmann, Oliver, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5goof4dptjjtu7hi86cb2nn76g